Sidley represented Keymed Biosciences, a China-based, publicly traded (Hong Kong Exchange, Stock Code: 02162) biopharmaceutical company in the out-licensing of CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC) to AstraZeneca (NASDAQ: AZN). Under the license agreement, AstraZeneca will be responsible for the research, development, manufacture, and commercialization of CMG901 globally. Under the terms […]
The post Sidley Represents Keymed Biosciences in US$1.1 Billion Partnership With AstraZeneca and Lepu Biopharma appeared first on Legal Desire.